What is the updated approach to diagnosing and treating lichen amyloidosis?

Lichen Amyloidosis: Updated Diagnosis and Treatment

I must clarify that the provided evidence exclusively addresses systemic amyloidosis (particularly cardiac AL amyloidosis) and does NOT contain guidelines for lichen amyloidosis, which is a completely different entity—a primary localized cutaneous amyloidosis without systemic involvement. Based on the limited but relevant research evidence provided, here is the current approach:

Diagnosis

Lichen amyloidosis is definitively diagnosed by skin biopsy showing amyloid deposits in the dermis with Congo red staining demonstrating apple-green birefringence under polarized microscopy 1, 2.

Clinical Presentation to Recognize:

• Discrete hyperkeratotic hyperpigmented papules, most commonly on the shins (86.7% of cases) 1
• Severe pruritus (present in 90% of patients) 1
• Duration typically 6-20 months before diagnosis
• History of chronic friction/scrubbing (56% of cases) 1
• Upper back is another common site 2

Diagnostic Workup:

1. Two punch biopsies: one for routine histopathology, one for immunofluorescence 1
2. Histopathology findings: Amorphous deposits at dermo-epidermal junction and dermis
3. Congo red staining: Essential for confirmation 1
4. Immunohistochemistry with high molecular weight cytokeratin (HMWCK): Positive in 63.6-66.7% of lichen amyloidosis cases, confirming keratinocyte origin 2
5. Direct immunofluorescence: Supplementary confirmation 1

Critical distinction: Unlike nodular amyloidosis (which shows light chain restriction and requires systemic workup), lichen amyloidosis derives from epidermal keratinocytes and does NOT require systemic evaluation 2.

Treatment

First-Line Approach:

Fractional CO2 laser therapy is emerging as the most effective treatment for refractory lichen amyloidosis, achieving rapid pruritus resolution (within 1 month) and long-term remission (up to 2 years) after a single session 3. This works by disrupting intraepidermal nerve fibers responsible for pruritus, even though dermal amyloid deposits persist 3.

Alternative Laser Option:

1064-nm Nd:YAG picosecond laser shows efficacy with improvement in lesion number, thickness, and darkness after five sessions at 4-week intervals 4.

Systemic Therapy for Generalized/Refractory Cases:

Dupilumab is the preferred systemic agent for generalized or treatment-resistant lichen amyloidosis 5, 6. It provides:

• Superior lesion resolution compared to JAK inhibitors
• Sustained pruritus control
• Minimal adverse effects
• Dual IL-4/IL-13 inhibition addresses underlying inflammation 5

Abrocitinib (100mg daily) provides rapid itch relief but shows minimal skin improvement and significant adverse effects (diarrhea, acneiform eruptions, herpes simplex reactivation) 5. It should be considered second-line or reserved for cases where dupilumab fails.

Traditional Therapies (Limited Efficacy):

• Topical/intralesional corticosteroids
• Topical tacrolimus
• These are appropriate only for very limited disease 6

Treatment Algorithm:

1. Localized disease: Fractional CO2 laser (single session) OR 1064-nm picosecond laser (5 sessions)
2. Generalized disease or laser failure: Dupilumab
3. Dupilumab contraindication/failure: Consider abrocitinib (with close monitoring for adverse effects)
4. Minimal disease: Topical corticosteroids or tacrolimus

Key Pitfalls to Avoid:

• Do not perform systemic amyloidosis workup (serum/urine protein electrophoresis, cardiac evaluation) unless nodular amyloidosis is suspected on biopsy with light chain restriction 2
• Do not rely solely on topical therapies for moderate-to-severe disease—they have poor efficacy
• Do not use abrocitinib as first-line systemic therapy—dupilumab shows superior lesion resolution 5
• Recognize that amyloid deposits may persist despite clinical resolution—treatment targets nerve fiber disruption and inflammation, not amyloid removal 3